Business Wire Feed

Long-Term Data Presented at the 22nd Annual WORLDSymposium™ Highlights Tralesinidase Alfa Enzyme Replacement Therapy’s Potential as the First Disease-Modifying Treatment Option for Sanfilippo Syndrome Type B (MPS IIIB)

February 5th, 2026|

Treatment with Weekly TA-ERT Demonstrated Rapid and Durable Normalization of Cerebral Spinal Fluid Heparan Sulfate Non-Reducing End (CSF HS-NRE), a Surrogate Endpoint Reasonably Likely to Predict Clinical Benefit TA-ERT Treatment Stabilized and Preserved Cognitive and more...

Adtalem Global Education Becomes Covista

February 5th, 2026|

Strategic transformation positions company as essential to healthcare workforce infrastructure Releases proprietary research platform on the U.S. healthcare workforce crisis Will discuss long-term strategy at February 24 Investor Day Unveils new commitment to expand healthcare more...

Fujirebio and Sysmex Begin Sales Collaboration for Dementia Testing

February 5th, 2026|

MINATO-KU, TOKYO, Japan & KOBE, Japan--(BUSINESS WIRE)--#IVD--Fujirebio Holdings, Inc. (HQ: Minato-ku, Tokyo; President & CEO: Goki Ishikawa; “Fujirebio”), a consolidated subsidiary of H.U. Group Holdings, Inc. (HQ: Minato-ku, Tokyo; Chairman, President and Group CEO: Shigekazu more...

JCR Pharmaceuticals’ Research Presentations at WORLDSymposium™ 2026 Showcase Data from Its Investigational Treatments for Lysosomal Storage Disorders

February 4th, 2026|

- Presentations Highlight Potential Benefits of Therapies Incorporating J-Brain Cargo®, JCR’s Proprietary, Blood-Brain Barrier-Penetrating Technology -HYOGO, Japan--(BUSINESS WIRE)--JCR Pharmaceuticals Co., Ltd. (TSE 4552; “JCR”), a global specialty biopharmaceutical company dedicated to developing therapies for rare more...

Guardant Health to Participate in Upcoming Investor Conferences

February 3rd, 2026|

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will be participating in the following investor conferences. BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic more...

Simulations Plus to Participate in Upcoming Investor Conferences

February 3rd, 2026|

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”, “SLP”), a global leader in model-informed and AI-accelerated drug development that advances biopharma innovation, today announced that Shawn O’Connor, Chief Executive Officer, will be more...

Subscribe to Our Newsletter

We keep your data private and share your data only with third parties that make this service possible. See our Privacy Policy for more information.